Novavax completed enrollment of PREVENT-19, COVID-19 vaccine pivotal phase 3 trial in the US and Mexico
On Feb. 22, 2021, Novavax announced it had completed enrollment of PREVENT-19, its pivotal Phase 3 study in…
Luminex received BARDA funding to support development and validation of test combining SARS-CoV-2 and Flu/RSV respiratory pane
On Feb. 19, 2021, Luminex announced that it had received $11.3 million in funding from the Biomedical Advanced…
Novavax announced MOU with Gavi for cumulative supply to COVAX facility of 11 billion doses of COVID-19 vaccine
On Feb. 18, 2021, Novavax and announced a Memorandum of Understanding (MOU) with Gavi, the Vaccine Alliance, to…
European Commission purchased additional 150 million doses of COVID-19 Vaccine Moderna
On Feb. 17, 2021, Moderna announced that the European Commission had purchased an additional 150 million doses of…
Pfizer and BioNTech announced supply the European Union with 200 million additional doses of COMIRNATY
On Feb. 17, 2021, BioNTech announced an agreement with the European Commission (EC) to supply an additional 200…
Anixa Biosciences began animal resting of Covid-19 therapeutic candidates
On Feb. 16, 2021, Anixa Biosciences announced that animal testing had commenced with two proprietary compounds that have…
Moderna provided U.S. COVID-19 vaccine supply update
On Feb. 16, 2021, Moderna provided a supply update for their COVID-19 Vaccine in the United States, reporting…
Novavax announced expanded agreement with SK Bioscience for 40 million doses of COVID-19 vaccine for South Korea
On Feb. 15, 2021, Novavax and SK Bioscience announced an expanded collaboration and license agreement. In addition to…
Canada purchased additional 4 million doses of Moderna’s COVID-19 vaccine
On Feb. 12, 2021, Moderna announced that the Canadian Government had increased its confirmed order commitment by 4…
Cue Health’s connected point-of-care Covid-19 test demonstrated 97.8% agreement compared to Central Lab PCR Testing
On Feb. 11, 2021, Cue Health announced the results of an independent clinical validation study conducted by Mayo…
Qatar Ministry of Public Health issued Emergency Use Authorization for COVID-19 Vaccine Moderna
On Feb. 11, 2021, Moderna announced that the Qatar Ministry of Public Health had issued an emergency use…
US Government purchased additional 100 million doses of Moderna’s COVID-19 Vaccine
On Feb. 11, 2021, Moderna announced that the U.S. government had purchased an additional 100 million doses of…
USDA confirmed COVID-19 in a cougar and tiger at a wild animal exhibitor in Texas
On Feb. 10, 2021, the United States Department of Agriculture (USDA) National Veterinary Services Laboratories announced confirmation of…
Moderna announced COVID-19 vaccine supply agreements with governments of Taiwan and Colombia
On Feb. 9, 2021, Moderna announced two supply agreements for the COVID-19 Vaccine Moderna: one with the government…
Novavax announced start of rolling review by multiple regulatory authorities for COVID-19 vaccine authorization
On Feb. 4, 2021, Novavax announced the start of the rolling review process for authorization of NVX-CoV2373, its…
Moderna announced amendment to supply agreement with Switzerland for additional 6 million doses of COVID-19 vaccine
On Feb. 3, 2021, Moderna announced the Swiss Federal Government had increased its confirmed order commitment from 7.5…
Singapore Health Sciences Authority approved interim authorization of COVID-19 Vaccine Moderna
On Feb. 3, 2021, Moderna announced that the Singapore Health Sciences Authority (HSA) had approved the interim authorization…
Novavax and Government of Switzerland announced agreement in principle to supply COVID-19 vaccine
On Feb. 3, 2021, Novavax announced that the company had executed a binding Heads of Terms agreement with…
Novavax announced MOU to produce COVID-19 vaccine made in Canada
On Feb. 2, 2021, Novavax announced a memorandum of understanding (MOU) with the Canadian government to produce NVX-CoV2373,…
Novavax COVID-19 vaccine demonstrated 89.3% efficacy in UK phase 3 trial
On Jan. 28, 2021, Novavax announced that NVX-CoV2373, its protein-based COVID-19 vaccine candidate, had met the primary endpoint,…
Vaxart announced publication that showed potential clinical and economic value of a Norovirus vaccine
On Jan. 27, 2021, Vaxart announced health care economic findings published in the American Journal of Preventative Medicine….
Moderna confirms discussions with US Government for additional 100 million doses of COVID-19 vaccine
On Jan. 27, 2021, Moderna confirmed that the Company is in discussion with the U.S. government to purchase…
Just – Evotec Biologics expanded contract with Department of Defense for manufacturing of monoclonal antibodies
On Jan. 27, 2021, Evotec announced that the U.S. Department of Defense (DOD) awarded its Seattle, Washington-based subsidiary,…
Moderna provided U.S. COVID-19 vaccine supply update
On Jan. 26, 2021, Moderna reported that 30.4 million doses have been supplied to the U.S. Government to…
Moderna COVID-19 vaccine retained neutralizing activity against emerging variants identified in UK and South Africa
On Jan. 25, 2021, Moderna announced results from in vitro neutralization studies of sera from individuals vaccinated with…
OHSU study revealed SARS-CoV-2 reacted to antibodies of virus from 2003 SARS outbreak
On Jan. 25, 2021, Oregon Health & Science University (OHSU) announced a new study demonstrated that antibodies generated…
Humanigen announced BARDA contract and Expansion of CRADA with U.S. Government for COVID-19
On Jan. 22, 2021, Humanigen announced an expansion to the Cooperative Research and Development Agreement (CRADA) that the…
Novavax and Government of Canada finalize advance purchase agreement for COVID-19 vaccine
On Jan. 22, 2021, Novavax announced that it had finalized an agreement with the Government of Canada to…
Zoetis Introducted Poulvac® Procerta™ HVT-IBD vaccine for infectious bursal disease
On Jan. 21, 2021, Zoetis announced it had as expanded its line of recombinant vector vaccines with the…
Moderna announced first participant dosed in phase 1/2 study of COVID-19 vaccine in Japan led by Takeda
On Jan. 21, 2021, Moderna announced that the first participant has been dosed in the Phase 1/2 study…